资讯
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861
Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from a randomized, double-blind, placebo-controlled, multiple dose Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2...